NASDAQ:BTCY Biotricity (BTCY) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free BTCY Stock Alerts $1.28 -0.02 (-1.54%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$1.22▼$1.3350-Day Range$0.92▼$1.6352-Week Range$0.70▼$4.45Volume128,361 shsAverage Volume84,924 shsMarket Capitalization$12.06 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Biotricity alerts: Email Address Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About Biotricity Stock (NASDAQ:BTCY)Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.Read More BTCY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BTCY Stock News HeadlinesApril 19, 2024 | finanznachrichten.deBiotricity, Inc.: Biotricity Launches Major Cardiac Monitoring Pilot Program in a Hospital System Comprised of 9 Hospitals and 10 ClinicsApril 17, 2024 | investing.comBiotricity pilots cardiac tech at major hospital networkApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.April 16, 2024 | finanznachrichten.deBiotricity, Inc.: Biotricity Launches Cardiac Monitoring Pilot Program with Major Hospital NetworkMarch 28, 2024 | finanznachrichten.deLOBO EV and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TVMarch 2, 2024 | finance.yahoo.comBiotricity, Inc. (BTCY) Interactive Stock Chart - Yahoo FinanceFebruary 29, 2024 | finanznachrichten.deBiotricity, Inc.: Biotricity Receives Health Canada Clearance for BiotresFebruary 22, 2024 | finance.yahoo.comBiotricity, Inc. (NASDAQ:BTCY) Q3 2024 Earnings Call TranscriptApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.February 21, 2024 | benzinga.comBiotricity Stock (NASDAQ:BTCY) Dividends: History, Yield and DatesFebruary 20, 2024 | finance.yahoo.comBiotricity Inc. (BTCY) Reports Q3 Loss, Misses Revenue EstimatesFebruary 20, 2024 | finanznachrichten.deBiotricity, Inc.: Biotricity to Host Third Quarter Fiscal Year 2024 Financial Results and Business Update Call on February 21stNovember 16, 2023 | finance.yahoo.comBiotricity, Inc. (NASDAQ:BTCY) Q2 2024 Earnings Call TranscriptNovember 14, 2023 | benzinga.comBiotricity Delivers Record Margins and Double Digit Year-Over-Year Sales Growth for Second Quarter of Fiscal Year 2024November 10, 2023 | finance.yahoo.comBiotricity to Host Second Quarter Fiscal Year 2024 Financial Results and Business Update Call on November 14thOctober 3, 2023 | finanznachrichten.deBiotricity, Inc.: Biotricity Announces Patient Filing for Cutting-Edge Biotres DeviceSeptember 13, 2023 | finance.yahoo.comBiotricity Unveils a New Digital Presence, Highlighting its Expanding Technology Portfolio and Cutting-Edge InnovationsAugust 30, 2023 | finanznachrichten.deBiotricity, Inc.: Biotricity Achieves $14 Million Revenue Run Rate in August 2023August 30, 2023 | finance.yahoo.comBiotricity Achieves $14 Million Revenue Run Rate in August 2023See More Headlines Receive BTCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biotricity and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/20/2024Today4/27/2024Next Earnings (Estimated)7/04/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Devices Sub-IndustryN/A Current SymbolNASDAQ:BTCY CUSIPN/A CIK1630113 Webwww.biotricity.com Phone(800) 590-4155FaxN/AEmployees55Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.3899) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,660,000.00 Net Margins-125.43% Pretax Margin-125.43% Return on EquityN/A Return on Assets-233.67% Debt Debt-to-Equity RatioN/A Current Ratio0.21 Quick Ratio0.10 Sales & Book Value Annual Sales$9.64 million Price / Sales1.25 Cash FlowN/A Price / Cash FlowN/A Book Value($2.27) per share Price / Book-0.56Miscellaneous Outstanding Shares9,420,000Free Float7,493,000Market Cap$12.06 million OptionableOptionable Beta1.51 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Waqaas Al-Siddiq Ph.D. (Age 39)Founder, President, CEO & Chairman Comp: $732kMr. S. John Ayanoglou (Age 57)Chief Financial Officer Comp: $305.75kMr. Andy WongVice President of OperationsDr. George N. NikopoulosDirector of Business DevelopmentMr. Matt ZabelVice President of Sales & StrategyMr. Amir AliChief Development OfficerMore ExecutivesKey CompetitorsPetVivoNASDAQ:PETVMicrobot MedicalNASDAQ:MBOTGlucoTrackNASDAQ:GCTKNEXGELNASDAQ:NXGLT2 BiosystemsNASDAQ:TTOOView All CompetitorsInstitutional OwnershipAdvisor Resource CouncilBought 79,070 shares on 4/19/2024Ownership: 0.839%Simplex Trading LLCSold 2,300 shares on 2/2/2024Ownership: 0.000%View All Institutional Transactions BTCY Stock Analysis - Frequently Asked Questions Should I buy or sell Biotricity stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biotricity in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" BTCY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BTCY, but not buy additional shares or sell existing shares. View BTCY analyst ratings or view top-rated stocks. How have BTCY shares performed in 2024? Biotricity's stock was trading at $1.15 at the beginning of the year. Since then, BTCY shares have increased by 11.3% and is now trading at $1.28. View the best growth stocks for 2024 here. Are investors shorting Biotricity? Biotricity saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 443,400 shares, an increase of 23.7% from the March 31st total of 358,400 shares. Based on an average daily volume of 96,900 shares, the days-to-cover ratio is presently 4.6 days. Currently, 5.6% of the shares of the stock are sold short. View Biotricity's Short Interest. When is Biotricity's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, July 4th 2024. View our BTCY earnings forecast. How were Biotricity's earnings last quarter? Biotricity, Inc. (NASDAQ:BTCY) posted its quarterly earnings results on Tuesday, February, 20th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.07. The firm earned $2.97 million during the quarter, compared to analysts' expectations of $3 million. When did Biotricity IPO? Biotricity (BTCY) raised $15 million in an IPO on Thursday, August 26th 2021. The company issued 5,000,000 shares at $3.00 per share. H.C. Wainwright & Co. served as the underwriter for the IPO. Who are Biotricity's major shareholders? Biotricity's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Advisor Resource Council (0.84%). How do I buy shares of Biotricity? Shares of BTCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BTCY) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biotricity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
